Crispino, S.P.; Segreti, A.; Nafisio, V.; Valente, D.; Crisci, F.; Ferro, A.; Cavallari, I.; Nusca, A.; Ussia, G.P.; Grigioni, F.
The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure. Biomedicines 2025, 13, 608.
https://doi.org/10.3390/biomedicines13030608
AMA Style
Crispino SP, Segreti A, Nafisio V, Valente D, Crisci F, Ferro A, Cavallari I, Nusca A, Ussia GP, Grigioni F.
The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure. Biomedicines. 2025; 13(3):608.
https://doi.org/10.3390/biomedicines13030608
Chicago/Turabian Style
Crispino, Simone Pasquale, Andrea Segreti, Vincenzo Nafisio, Daniele Valente, Filippo Crisci, Aurora Ferro, Ilaria Cavallari, Annunziata Nusca, Gian Paolo Ussia, and Francesco Grigioni.
2025. "The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure" Biomedicines 13, no. 3: 608.
https://doi.org/10.3390/biomedicines13030608
APA Style
Crispino, S. P., Segreti, A., Nafisio, V., Valente, D., Crisci, F., Ferro, A., Cavallari, I., Nusca, A., Ussia, G. P., & Grigioni, F.
(2025). The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure. Biomedicines, 13(3), 608.
https://doi.org/10.3390/biomedicines13030608
